Peroxisome proliferator-activated receptor α-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload

Toni Ann S Duhaney, Lei Cui, Mary K. Rude, Nathan K LeBrasseur, Soeun Ngoy, Deepa S. De Silva, Deborah A. Siwik, Ronglih Liao, Flora Sam

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Progressive cardiac remodeling is characterized by subsequent chamber hypertrophy, enlargement, and pump dysfunction. It is also associated with increased cardiac fibrosis and matrix turnover. Interestingly, peroxisome proliferator-activated receptor (PPAR) α activators reduce cardiac hypertrophy, inflammation, and fibrosis. Little is known about the role of fenofibrates in mediating PPARα-independent effects in response to chronic pressure overload (PO). Wild-type and PPARα-deficient mice were subjected to chronic PO caused by ascending aortic constriction to test the role of fenofibrates in chronic, progressive cardiac remodeling by a PPARα-independent mechanism. Mice were randomized to regular chow or chow-containing fenofibrate (100 mg/kg of body weight per day) for 1 week before and 8 weeks after ascending aortic constriction. In the presence of PPARα, wild-type chronic PO mice, treated with fenofibrate, had improved cardiac remodeling. However, PO PPARα-deficient mice treated with fenofibrate had increased mortality, significantly adverse left ventricular end diastolic (3.4±0.1 versus 4.2±0.1 mm) and end systolic (1.5±0.2 versus 2.5±0.2 mm) dimensions, and fractional shortening (57±3% versus 40±3%). Fenofibrate also increased myocardial hypertrophy, cardiac fibrosis, and the ratio of matrix metalloproteinase-2/ tissue inhibitor of matrix metalloproteinase-2 in PO PPARα-deficient mice. Fenofibrate inhibited matrix metalloproteinase activity in vitro and aldosterone-induced increases in extracellular signal-regulated kinase phosphorylation. Thus, fenofibrate improved cardiac remodeling in chronic PO mice. However, in PPARα-deficient mice, this chronic PO was exacerbated and associated with increased myocardial fibrosis and altered matrix remodeling. In the absence of PPARα, fenofibrates exerts deleterious, pleiotropic myocardial actions. This is an important observation, because PPARα agonists are considered possible inhibitory regulators of cardiac remodeling in the remodeled heart.

Original languageEnglish (US)
Pages (from-to)1084-1094
Number of pages11
JournalHypertension
Volume49
Issue number5
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Fenofibrate
Peroxisome Proliferator-Activated Receptors
Dilatation
Fibrosis
Pressure
Matrix Metalloproteinase 2
Cardiomegaly
Constriction
Tissue Inhibitor of Metalloproteinase-2
Extracellular Signal-Regulated MAP Kinases
Aldosterone
Matrix Metalloproteinases
Hypertrophy
Body Weight
Phosphorylation
Observation
Inflammation

Keywords

  • Fibrosis
  • Matrix metalloproteinases
  • Peroxisome proliferator-activated receptor
  • Pressure overload
  • Ventricular remodeling

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Peroxisome proliferator-activated receptor α-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. / Duhaney, Toni Ann S; Cui, Lei; Rude, Mary K.; LeBrasseur, Nathan K; Ngoy, Soeun; De Silva, Deepa S.; Siwik, Deborah A.; Liao, Ronglih; Sam, Flora.

In: Hypertension, Vol. 49, No. 5, 05.2007, p. 1084-1094.

Research output: Contribution to journalArticle

Duhaney, Toni Ann S ; Cui, Lei ; Rude, Mary K. ; LeBrasseur, Nathan K ; Ngoy, Soeun ; De Silva, Deepa S. ; Siwik, Deborah A. ; Liao, Ronglih ; Sam, Flora. / Peroxisome proliferator-activated receptor α-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. In: Hypertension. 2007 ; Vol. 49, No. 5. pp. 1084-1094.
@article{0e27a493903a4a89bb575058c098985e,
title = "Peroxisome proliferator-activated receptor α-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload",
abstract = "Progressive cardiac remodeling is characterized by subsequent chamber hypertrophy, enlargement, and pump dysfunction. It is also associated with increased cardiac fibrosis and matrix turnover. Interestingly, peroxisome proliferator-activated receptor (PPAR) α activators reduce cardiac hypertrophy, inflammation, and fibrosis. Little is known about the role of fenofibrates in mediating PPARα-independent effects in response to chronic pressure overload (PO). Wild-type and PPARα-deficient mice were subjected to chronic PO caused by ascending aortic constriction to test the role of fenofibrates in chronic, progressive cardiac remodeling by a PPARα-independent mechanism. Mice were randomized to regular chow or chow-containing fenofibrate (100 mg/kg of body weight per day) for 1 week before and 8 weeks after ascending aortic constriction. In the presence of PPARα, wild-type chronic PO mice, treated with fenofibrate, had improved cardiac remodeling. However, PO PPARα-deficient mice treated with fenofibrate had increased mortality, significantly adverse left ventricular end diastolic (3.4±0.1 versus 4.2±0.1 mm) and end systolic (1.5±0.2 versus 2.5±0.2 mm) dimensions, and fractional shortening (57±3{\%} versus 40±3{\%}). Fenofibrate also increased myocardial hypertrophy, cardiac fibrosis, and the ratio of matrix metalloproteinase-2/ tissue inhibitor of matrix metalloproteinase-2 in PO PPARα-deficient mice. Fenofibrate inhibited matrix metalloproteinase activity in vitro and aldosterone-induced increases in extracellular signal-regulated kinase phosphorylation. Thus, fenofibrate improved cardiac remodeling in chronic PO mice. However, in PPARα-deficient mice, this chronic PO was exacerbated and associated with increased myocardial fibrosis and altered matrix remodeling. In the absence of PPARα, fenofibrates exerts deleterious, pleiotropic myocardial actions. This is an important observation, because PPARα agonists are considered possible inhibitory regulators of cardiac remodeling in the remodeled heart.",
keywords = "Fibrosis, Matrix metalloproteinases, Peroxisome proliferator-activated receptor, Pressure overload, Ventricular remodeling",
author = "Duhaney, {Toni Ann S} and Lei Cui and Rude, {Mary K.} and LeBrasseur, {Nathan K} and Soeun Ngoy and {De Silva}, {Deepa S.} and Siwik, {Deborah A.} and Ronglih Liao and Flora Sam",
year = "2007",
month = "5",
doi = "10.1161/HYPERTENSIONAHA.107.086926",
language = "English (US)",
volume = "49",
pages = "1084--1094",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor α-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload

AU - Duhaney, Toni Ann S

AU - Cui, Lei

AU - Rude, Mary K.

AU - LeBrasseur, Nathan K

AU - Ngoy, Soeun

AU - De Silva, Deepa S.

AU - Siwik, Deborah A.

AU - Liao, Ronglih

AU - Sam, Flora

PY - 2007/5

Y1 - 2007/5

N2 - Progressive cardiac remodeling is characterized by subsequent chamber hypertrophy, enlargement, and pump dysfunction. It is also associated with increased cardiac fibrosis and matrix turnover. Interestingly, peroxisome proliferator-activated receptor (PPAR) α activators reduce cardiac hypertrophy, inflammation, and fibrosis. Little is known about the role of fenofibrates in mediating PPARα-independent effects in response to chronic pressure overload (PO). Wild-type and PPARα-deficient mice were subjected to chronic PO caused by ascending aortic constriction to test the role of fenofibrates in chronic, progressive cardiac remodeling by a PPARα-independent mechanism. Mice were randomized to regular chow or chow-containing fenofibrate (100 mg/kg of body weight per day) for 1 week before and 8 weeks after ascending aortic constriction. In the presence of PPARα, wild-type chronic PO mice, treated with fenofibrate, had improved cardiac remodeling. However, PO PPARα-deficient mice treated with fenofibrate had increased mortality, significantly adverse left ventricular end diastolic (3.4±0.1 versus 4.2±0.1 mm) and end systolic (1.5±0.2 versus 2.5±0.2 mm) dimensions, and fractional shortening (57±3% versus 40±3%). Fenofibrate also increased myocardial hypertrophy, cardiac fibrosis, and the ratio of matrix metalloproteinase-2/ tissue inhibitor of matrix metalloproteinase-2 in PO PPARα-deficient mice. Fenofibrate inhibited matrix metalloproteinase activity in vitro and aldosterone-induced increases in extracellular signal-regulated kinase phosphorylation. Thus, fenofibrate improved cardiac remodeling in chronic PO mice. However, in PPARα-deficient mice, this chronic PO was exacerbated and associated with increased myocardial fibrosis and altered matrix remodeling. In the absence of PPARα, fenofibrates exerts deleterious, pleiotropic myocardial actions. This is an important observation, because PPARα agonists are considered possible inhibitory regulators of cardiac remodeling in the remodeled heart.

AB - Progressive cardiac remodeling is characterized by subsequent chamber hypertrophy, enlargement, and pump dysfunction. It is also associated with increased cardiac fibrosis and matrix turnover. Interestingly, peroxisome proliferator-activated receptor (PPAR) α activators reduce cardiac hypertrophy, inflammation, and fibrosis. Little is known about the role of fenofibrates in mediating PPARα-independent effects in response to chronic pressure overload (PO). Wild-type and PPARα-deficient mice were subjected to chronic PO caused by ascending aortic constriction to test the role of fenofibrates in chronic, progressive cardiac remodeling by a PPARα-independent mechanism. Mice were randomized to regular chow or chow-containing fenofibrate (100 mg/kg of body weight per day) for 1 week before and 8 weeks after ascending aortic constriction. In the presence of PPARα, wild-type chronic PO mice, treated with fenofibrate, had improved cardiac remodeling. However, PO PPARα-deficient mice treated with fenofibrate had increased mortality, significantly adverse left ventricular end diastolic (3.4±0.1 versus 4.2±0.1 mm) and end systolic (1.5±0.2 versus 2.5±0.2 mm) dimensions, and fractional shortening (57±3% versus 40±3%). Fenofibrate also increased myocardial hypertrophy, cardiac fibrosis, and the ratio of matrix metalloproteinase-2/ tissue inhibitor of matrix metalloproteinase-2 in PO PPARα-deficient mice. Fenofibrate inhibited matrix metalloproteinase activity in vitro and aldosterone-induced increases in extracellular signal-regulated kinase phosphorylation. Thus, fenofibrate improved cardiac remodeling in chronic PO mice. However, in PPARα-deficient mice, this chronic PO was exacerbated and associated with increased myocardial fibrosis and altered matrix remodeling. In the absence of PPARα, fenofibrates exerts deleterious, pleiotropic myocardial actions. This is an important observation, because PPARα agonists are considered possible inhibitory regulators of cardiac remodeling in the remodeled heart.

KW - Fibrosis

KW - Matrix metalloproteinases

KW - Peroxisome proliferator-activated receptor

KW - Pressure overload

KW - Ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=34247880263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247880263&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.107.086926

DO - 10.1161/HYPERTENSIONAHA.107.086926

M3 - Article

VL - 49

SP - 1084

EP - 1094

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 5

ER -